16.1% on semaglutide Tirzepatide was superior on all five key secondary endpoints Gastrointestinal discontinuation rate was lower with tirzepatide (2.7%) than semaglutide (5.6%) These findings were consistent across all patient subgroups, regardless of sex, age, baseline BMI, or presence of metabolic comorbidities
Combining Mod GRF 1-29 with GHRPs can lead to synergistic effects, significantly boosting growth hormone secretion
Dermatologists typically recommend a fixed daily dose taken consistently
Hoang VM, Le TV, Chu TTQ, Le BN, Duong MD, Thanh NM, et al
Rare but serious risks include pancreatitis and gallbladder issues